| 1 |
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology
Open access |
22 Feb 2009 |
2,681 |
| 2 |
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael G. Pfreundschuh et al. · The Lancet Oncology
|
7 Apr 2006 |
2,098 |
| 3 |
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Tim Hughes · Blood
Open access |
7 Mar 2006 |
1,209 |
| 4 |
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Hervé Dombret et al. · Blood
Open access |
18 May 2015 |
1,168 |
| 5 |
The P2X7 Receptor: A Key Player in IL-1 Processing and Release
Davide Ferrari, Cinzia Pizzirani, Elena Adinolfi et al. · The Journal of Immunology
|
Apr 2006 |
1,032 |
| 6 |
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
Evangelos Terpos et al. · Haematologica
Open access |
Oct 2015 |
994 |
| 7 |
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Philippe Moreau, Jesús F. San Miguel, Pieter Sonneveld et al. · Annals of Oncology
Open access |
6 Apr 2017 |
882 |
| 8 |
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients
Stefano Aldo Pileri et al. · Leukemia
|
14 Dec 2006 |
718 |
| 9 |
Multipotent Mesenchymal Stem Cells with Immunosuppressive Activity Can Be Easily Isolated from Dental Pulp
Laura Pierdomenico, Laura Bonsi, Mario Calvitti et al. · Transplantation
|
27 Sep 2005 |
611 |
| 10 |
IMWG consensus on risk stratification in multiple myeloma
Wee Joo Chng, Angela Dispenzieri, C-S Chim et al. · Leukemia
|
26 Aug 2013 |
604 |
| 11 |
Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro
Francesco Alviano, Valentina Fossati, Cosetta Marchionni et al. · BMC Developmental Biology
Open access |
21 Feb 2007 |
442 |
| 12 |
Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer
Umberto Veronesi et al. · JNCI Journal of the National Cancer Institute
|
3 Nov 1999 |
421 |
| 13 |
2011: the immune hallmarks of cancer
Federica Cavallo, Carla De Giovanni, Patrizia Nanni et al. · Cancer Immunology Immunotherapy
Open access |
25 Jan 2011 |
419 |
| 14 |
Successful Validation of the Palliative Prognostic Score in Terminally Ill Cancer Patients
Marco Cesare Maltoni, Oriana Nanni, Marco Pirovano et al. · Journal of Pain and Symptom Management
Open access |
Apr 1999 |
419 |
| 15 |
A New Palliative Prognostic Score
Marco Pirovano, Marco Cesare Maltoni, Oriana Nanni et al. · Journal of Pain and Symptom Management
Open access |
Apr 1999 |
418 |
| 16 |
Validation of a food-frequency questionnaire to assess dietary intakes in cancer studies in Italy results for specific nutrients
Adriano Decarli, Silvia Franceschi, Monica Ferraroni et al. · Annals of Epidemiology
|
Mar 1996 |
415 |
| 17 |
Coded aperture imaging in X- and gamma-ray astronomy
E. Caroli, J. B. Stephen, G. Di Cocco et al. · Space Science Reviews
|
Sep 1987 |
409 |
| 18 |
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark J. Levis et al. · Blood
Open access |
26 Jan 2011 |
405 |
| 19 |
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma
Thomas Elmer Witzig, Julie Marie Vose, Pier Luigi Zinzani et al. · Annals of Oncology
Open access |
13 Jan 2011 |
396 |
| 20 |
The effects of imatinib on pregnancy outcome
Seonaid Pye, Jörge E. Cortes, Patricia S Ault et al. · Blood
Open access |
6 Mar 2008 |
396 |
| 21 |
Risk of Recurrence After a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor
Alfonso Iorio, Clive Kearon, Esmeralda Filippucci et al. · Archives of Internal Medicine
|
25 Oct 2010 |
384 |
| 22 |
Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome–positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol
Marco Vignetti, Paola Fazi, Giuseppe G. Cimino et al. · Blood
Open access |
9 Jan 2007 |
375 |
| 23 |
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
Michèle Cavo, Elena Zamagni, Patrizia Tosi et al. · Blood
|
11 Mar 2005 |
370 |
| 24 |
Peripheral T-cell lymphoma
Francine M. Foss, Pier Luigi Zinzani, Julie Marie Vose et al. · Blood
Open access |
15 Apr 2011 |
353 |
| 25 |
Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study
Livio Pagano et al. · Haematologica
Open access |
22 Oct 2009 |
316 |
| 26 |
Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype
Francisco J. Hernandez‐Ilizaliturri, George Michael Deeb, Pier Luigi Zinzani et al. · Cancer
|
14 Apr 2011 |
308 |
| 27 |
Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer.
Monica Santimaria, Giovanni Moscatelli, Giuseppe Viale et al. · PubMed
|
Feb 2003 |
294 |
| 28 |
Exercises for paretic upper limb after stroke: A combined virtual-reality and telemedicine approach
L. Piron, Andrea Turolla, Michela Agostini et al. · Journal of Rehabilitation Medicine
Open access |
2009 |
282 |
| 29 |
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
Andrew G Spencer et al. · Haematologica
Open access |
20 Sep 2018 |
262 |
| 30 |
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
Francesco F. Zaja et al. · Blood
|
3 Feb 2010 |
262 |
| 31 |
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer
Sabina Signoretti, Lucia Di Marcotullio, Andrea L. Richardson et al. · Journal of Clinical Investigation
Open access |
Sep 2002 |
256 |
| 32 |
Reproducibility of an Italian food frequency questionnaire for cancer studies
Silvia Franceschi, Fabio Barbone, Eva Negri et al. · Annals of Epidemiology
|
1995 |
246 |
| 33 |
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
Heinz Ludwig et al. · Blood
Open access |
12 Feb 2008 |
234 |
| 34 |
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
Shaji Kunnathu Kumar et al. · Blood
Open access |
27 Jun 2009 |
234 |
| 35 |
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
Simona Soverini, Manuela Mancini, Luana Bavaro et al. · Molecular Cancer
Open access |
15 Feb 2018 |
232 |
| 36 |
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis
Sara Trabanelli et al. · Nature Communications
Open access |
13 Sep 2017 |
232 |
| 37 |
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
Sergio A. Giralt et al. · Leukemia
|
25 Jun 2009 |
232 |
| 38 |
Altered pre-lamin A processing is a common mechanism leading to lipodystrophy
Cristina Capanni, Elisabetta Mattioli, Marta Columbaro et al. · Human Molecular Genetics
|
20 Apr 2005 |
226 |
| 39 |
Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients
Pier Luigi Zinzani, Gianandrea Baliva, Massimo Magagnoli et al. · Journal of Clinical Oncology
|
Jul 2000 |
226 |
| 40 |
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
Michael G. Pfreundschuh, Anthony Dick Ho, Eva K. Cavallin-Ståhl et al. · The Lancet Oncology
|
8 Apr 2008 |
223 |
| 41 |
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP)
Ilaria Iacobucci et al. · Blood
Open access |
10 Jul 2009 |
222 |
| 42 |
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Monika Martha Engelhardt et al. · Haematologica
Open access |
Feb 2014 |
213 |
| 43 |
Impact of delirium on the short term prognosis of advanced cancer patients
Augusto Tommaso Caraceni, Oriana Nanni, Marco Cesare Maltoni et al. · Cancer
|
Sep 2000 |
204 |
| 44 |
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
Jörge E. Cortes et al. · Leukemia
|
28 Aug 2008 |
201 |
| 45 |
Prediction of survival of patients terminally III with cancer. Results of an Italian prospective multicentric study
Marco Cesare Maltoni, Marco Pirovano, Emanuela Scarpi et al. · Cancer
Open access |
15 May 1995 |
197 |
| 46 |
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome
Pier Luigi Zinzani, Filippo Venturini, Vittorio Stefoni et al. · Annals of Oncology
Open access |
4 Nov 2009 |
196 |
| 47 |
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
Simona Soverini, Sabrina Colarossi, Alessandra Gnani et al. · Haematologica
Open access |
Mar 2007 |
191 |
| 48 |
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation
Franck Morschhauser, Tim Illidge, Damien G. Huglo et al. · Blood
|
26 Mar 2007 |
187 |
| 49 |
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti et al. · Journal of Clinical Oncology
Open access |
9 Aug 2019 |
185 |
| 50 |
Food groups and risk of colorectal cancer in Italy
Silvia Franceschi, Adriano Favero, Carlo La Vecchia et al. · International Journal of Cancer
|
3 Jul 1997 |
185 |